Market Overview

Spinocerebellar Ataxia| A Drug Pipeline Analysis Report 2018| Technavio


Technavio has announced their latest drug pipeline analysis report on spinocerebellar
. The report includes a detailed analysis of the pipeline
molecules under investigation within the defined data collection period
to treat spinocerebellar ataxia.

This press release features multimedia. View the full release here:

Technavio has published a new report on the drug development pipeline for spinocerebellar ataxia, in ...

Technavio has published a new report on the drug development pipeline for spinocerebellar ataxia, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
market snapshot before purchasing

Spinocerebellar ataxia: Market overview

Spinocerebellar ataxia (SCA) is a hereditary disease caused due to
mutations in the ATXN1 gene. Mutation in ATXN1 gene can lead to
degenerative changes in the cerebellum and spinal cord. A person
affected by the disease usually inherits the altered gene from an
affected parent. The gene is passed down from one generation to the next.

According to a senior market research analyst at Technavio, "The
National Institutes of Health stated in their research that one to two
per 100,000 people worldwide are affected by spinocerebellar ataxia.
Spinocerebellar ataxia type 3, also called the Machado-Joseph disease,
is an inherited form of ataxia that is characterized by the progressive
clumsiness in arms and legs. The MJD can be segmented into three types
such as Type I, type II, and type III."

Spinocerebellar ataxia: Segmentation analysis

This pipeline analysis report segments the spinocerebellar ataxia market
based on RoA (IV, oral, and sublingual), therapeutic modality (small
molecule, gene therapy, and stem cell), geographical segmentation
(Israel, Japan, Taiwan, and US) and recruitment status (active, not
recruiting, completed, and recruiting). It provides an in-depth analysis
of the prominent factors influencing the market, including drivers,
opportunities, trends, and industry-specific challenges.

Based on therapeutic modalities, close to 64% of the molecules that are
being investigated for the treatment of spinocerebellar ataxia are small

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team

View Comments and Join the Discussion!